Clinical Trials · NCT04982575
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 92
- Start date
- Aug 2021
- Locations
- 23 sites, United States
- Primary endpoint
- Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)